Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Lisa Sengeløv"'
Publikováno v:
Supportive Care in Cancer. 28:939-950
The newly developed “Herlev Hospital Empowerment of Relatives through More and Earlier information Supply” (HERMES) intervention systematically identifies cancer caregivers’ unmet needs for information from health care professionals (HCPs) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f992c2577a9a7633cdb8930102f8aff
https://doi.org/10.1007/s00520-019-04900-3
https://doi.org/10.1007/s00520-019-04900-3
Autor:
Lisa Sengeløv, Neeraj Agarwal, Christopher J. Logothetis, Eugene D. Kwon, Michael Krainer, Fabio Franke, Karim Fizazi, Charles G. Drake, Ernesto Korbenfeld, Hakim Mahammedi, Winald R. Gerritsen, Tomasz M. Beer, Allen C. Chen, Alberto Bossi, Nadine Houede, Siobhan Ng, Riccardo Danielli, Ricardo Santos, M. Brent McHenry, Steinbjørn Hansen, Santhanam Sundar, Alfons J.M. van den Eertwegh, Andre M. Bergman, Tudor Ciuleanu, Howard I. Scher
Publikováno v:
European Urology, 78, 822-830
European Urology, 78, 6, pp. 822-830
Fizazi, K, Drake, C G, Beer, T M, Kwon, E D, Scher, H I, Gerritsen, W R, Bossi, A, den Eertwegh, A J M V, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Danielli, R, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengeløv, L, Hansen, S, McHenry, M B, Chen, A, Logothetis, C & for the CA184-043, Investigators 2020, ' Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors ', European Urology, vol. 78, no. 6, pp. 822-830 . https://doi.org/10.1016/j.eururo.2020.07.032
Eur Urol
European Urology
European Urology, Elsevier, 2020, 78 (6), pp.822-830. ⟨10.1016/j.eururo.2020.07.032⟩
European Urology, 78(6), 822-830. Elsevier
European Urology, 78, 6, pp. 822-830
Fizazi, K, Drake, C G, Beer, T M, Kwon, E D, Scher, H I, Gerritsen, W R, Bossi, A, den Eertwegh, A J M V, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Danielli, R, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengeløv, L, Hansen, S, McHenry, M B, Chen, A, Logothetis, C & for the CA184-043, Investigators 2020, ' Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors ', European Urology, vol. 78, no. 6, pp. 822-830 . https://doi.org/10.1016/j.eururo.2020.07.032
Eur Urol
European Urology
European Urology, Elsevier, 2020, 78 (6), pp.822-830. ⟨10.1016/j.eururo.2020.07.032⟩
European Urology, 78(6), 822-830. Elsevier
BACKGROUND: The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel previously. In a prior analysis, the tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::499db8fbbd4f77d9c93e4583eef8b0fb
http://hdl.handle.net/2066/228533
http://hdl.handle.net/2066/228533
Autor:
Per Kongsted, Rikke Andersen, Eva Ellebaek, Lisa Sengeløv, Trine Zeeberg Iversen, Özcan Met, Henriette Lindberg, Troels Holz Borch, Inge Marie Svane, Morten Hartvig Hansen
Publikováno v:
Cytotherapy. 19:500-513
Background aims We investigated whether the addition of an autologous dendritic cell–based cancer vaccine (DCvac) induces an immune response in patients with metastatic castration-resistant prostate cancer treated with docetaxel. Methods Forty-thre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e4490cdc881dff19527abc18a1305c
https://doi.org/10.1016/j.jcyt.2017.01.007
https://doi.org/10.1016/j.jcyt.2017.01.007
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 28(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::723a8ffd627d56c67880fb3538b42661
https://pubmed.ncbi.nlm.nih.gov/31720826
https://pubmed.ncbi.nlm.nih.gov/31720826
Autor:
Lisa Sengeløv, Jianping Zhang, Cora N. Sternberg, Mads Agerbæk, Gedske Daugaard, Linda Cerbone, Sandrine Marreaud, Sandra Collette, Carla M.L. van Herpen
Publikováno v:
Oncology (Basel: 1948), 90, 1, pp. 21-8
Oncology (Basel: 1948), 90, 21-8
Cerbone, L, Sternberg, C N, Sengeløv, L, Agerbaek, M, Van Herpen, C, Marreaud, S, Collette, S, Zhang, J & Daugaard, G 2016, ' Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061 ', Oncology, vol. 90, no. 1, pp. 21-8 . https://doi.org/10.1159/000440959
Oncology (Basel: 1948), 90, 21-8
Cerbone, L, Sternberg, C N, Sengeløv, L, Agerbaek, M, Van Herpen, C, Marreaud, S, Collette, S, Zhang, J & Daugaard, G 2016, ' Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061 ', Oncology, vol. 90, no. 1, pp. 21-8 . https://doi.org/10.1159/000440959
Background/Objective: Lapatinib is a potent HER1 and HER2 inhibitor. Gemcitabine-cisplatin (GC) is a standard chemotherapy regimen for advanced/metastatic bladder cancer. This phase I study examined the safety of lapatinib in combination with GC in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0c5344e76e4dd7f096528d565ee5eda
https://doi.org/10.1159/000440959
https://doi.org/10.1159/000440959
Autor:
Joen Sveistrup, Morten Høyer, Steinbjørn Hansen, Peter Meidahl Petersen, S.E. Petersen, Michael Borre, Lisa Sengeløv, Maria Ervandian, Mats Holmberg
Publikováno v:
Ervandian, M, Høyer, M, Petersen, S E, Sengeløv, L, Hansen, S, Holmberg, M, Sveistrup, J, Meidahl Petersen, P & Borre, M 2016, ' Salvage radiation therapy following radical prostatectomy : A national Danish study ', Acta Oncologica, vol. 55, no. 5, pp. 598-603 . https://doi.org/10.3109/0284186X.2015.1088170
Ervandian, M, Høyer, M, Petersen, S E, Sengeløv, L, Hansen, S, Holmberg, M, Sveistrup, J, Meidahl Petersen, P & Borre, M 2015, ' Salvage radiation therapy following radical prostatectomy. A national Danish study ', Acta Oncologica, pp. 1-6 . https://doi.org/10.3109/0284186X.2015.1088170
Ervandian, M, Høyer, M, Petersen, S E, Sengeløv, L, Hansen, S, Holmberg, M, Sveistrup, J, Meidahl Petersen, P & Borre, M 2015, ' Salvage radiation therapy following radical prostatectomy. A national Danish study ', Acta Oncologica, pp. 1-6 . https://doi.org/10.3109/0284186X.2015.1088170
BACKGROUND: The purpose of this observational cohort study was to evaluate the outcome and prognostic factors following salvage radiotherapy (SRT) in a consecutive national cohort.MATERIAL AND METHODS: Between 2006 and 2010, 259 patients received SRT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f682f0665d2252db9fc44780f45ef2
https://doi.org/10.3109/0284186x.2015.1088170
https://doi.org/10.3109/0284186x.2015.1088170
Autor:
Lisa Sengeløv, Nathalie Germann, M. Moe, Frederique Baton, Cora N. Sternberg, L. Stachurski, Joaquim Bellmunt, Gedske Daugaard, Albertas Ulys, Sylvain Ladoire, Aude Flechon, Miguel Angel Climent, Herlinde Dumez, A. Guida, Michaela Matouskova, Simon Chowdhury, Karim Fizazi, Sigita Liutkauskiene, Nicolas Penel, Antoine Thiery-Vuillemin
Publikováno v:
Annals of Oncology
Annals of Oncology, Oxford University Press (OUP), 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, Elsevier, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, Oxford University Press (OUP), 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
Annals of Oncology, Elsevier, 2017, 28 (11), pp.2741-2746. ⟨10.1093/annonc/mdx487⟩
IF 11.855; International audience; BackgroundThis phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73b2b9838b5165a3d969ca8d5836968
https://hal.archives-ouvertes.fr/hal-01698533
https://hal.archives-ouvertes.fr/hal-01698533
Autor:
Lisa Sengeløv, Paul N. Mainwaring, Fred Saad, Oliver Sartor, Orazio Caffo, Marie Hjälm-Eriksson, John Bernard, Gedske Daugaard, Liji Shen, Steinbjørn Hansen, Antoine Thiery-Vuillemin, Karim Fizazi, Daniel Castellano, Mustapha Chadjaa, Jacek Jassem, Stéphane Oudard
Publikováno v:
Oudard, S, Fizazi, K, Sengeløv, L, Daugaard, G, Saad, F, Hansen, S, Hjälm-Eriksson, M, Jassem, J, Thiery-Vuillemin, A, Caffo, O, Castellano, D, Mainwaring, P N, Bernard, J, Shen, L, Chadjaa, M & Sartor, O 2017, ' Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer : A Randomized Phase III Trial-FIRSTANA ', Journal of Clinical Oncology, vol. 35, no. 28, pp. 3189-3197 . https://doi.org/10.1200/JCO.2016.72.1068
Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is significantly improved with cabazitaxel versus mitoxantrone after prior docetaxel treatment. FIRSTANA ( ClinicalTrials.gov identifier: NCT01308
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a6f132402d2a7f18265de183ed22694
https://pubmed.ncbi.nlm.nih.gov/29642359
https://pubmed.ncbi.nlm.nih.gov/29642359
Autor:
Arvind Varma, Josep M. Piulats, Lisa Sengeløv, Charles G. Drake, Fred Saad, Piotr Humanski, Gwenaelle Gravis, Roman Carvajal, Jonathan Polikoff, J. Puente, Vinod Ganju, M. Brent McHenry, Karim Fizazi, Eugene D. Kwon, Fabio Franke, Tomasz M. Beer, Alfonsus J. M. van den Eertwegh, Winald R. Gerritsen, Siobhan Ng, Christopher J. Logothetis, Francis Parnis, Dirk Jaeger, Pablo González Mella
Publikováno v:
Journal of Clinical Oncology, 35(1), 40-47. American Society of Clinical Oncology
Journal of Clinical Oncology, 35, 40-47
Beer, T M, Kwon, E D, Drake, C G, Fizazi, K, Logothetis, C, Gravis, G, Ganju, V, Polikoff, J, Saad, F, Humanski, P, Piulats, J M, Gonzalez Mella, P, Ng, S S, Jaeger, D, Parnis, F X, Franke, F A, Puente, J, Carvajal, R, Sengeløv, L, McHenry, M B, Varma, A, van den Eertwegh, A J & Gerritsen, W 2017, ' Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer ', Journal of Clinical Oncology, vol. 35, no. 1, pp. 40-47 .
Journal of Clinical Oncology, 35, 1, pp. 40-47
Journal of Clinical Oncology, 35, 40-47
Beer, T M, Kwon, E D, Drake, C G, Fizazi, K, Logothetis, C, Gravis, G, Ganju, V, Polikoff, J, Saad, F, Humanski, P, Piulats, J M, Gonzalez Mella, P, Ng, S S, Jaeger, D, Parnis, F X, Franke, F A, Puente, J, Carvajal, R, Sengeløv, L, McHenry, M B, Varma, A, van den Eertwegh, A J & Gerritsen, W 2017, ' Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer ', Journal of Clinical Oncology, vol. 35, no. 1, pp. 40-47 .
Journal of Clinical Oncology, 35, 1, pp. 40-47
Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33682fda3cd36d235c61a4debd4560a0
https://research.vumc.nl/en/publications/9a14b090-f1f1-4404-890f-7cd520128157
https://research.vumc.nl/en/publications/9a14b090-f1f1-4404-890f-7cd520128157
Autor:
Lisa Sengeløv, S.E. Petersen, Michael Borre, Maria Ervandian, Peter Meidahl Petersen, Steinbjørn Hansen, Morten Høyer, Mette Moe Kempel
Publikováno v:
Ervandian, M, Høyer, M, Petersen, S E, Sengeløv, L, Hansen, S, Kempel, M M, Meidahl Petersen, P & Borre, M 2017, ' Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer() ', Scandinavian Journal of Urology, vol. 51, no. 6, pp. 457-463 . https://doi.org/10.1080/21681805.2017.1354314
Ervandian, M, Høyer, M, Petersen, S, Sengeløv, L, Hansen, S, Kempel, M M, Petersen, P & Borre, M 2017, ' Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer ', Scandinavian Journal of Urology, vol. 51, no. 220, 24, pp. 28-29 . https://doi.org/10.1080/21681805.2017.1332285
Ervandian, M, Hoyer, M, Petersen, S E, Sengelov, L, Hansen, S, Kempel, M M, Petersen, P M & Borre, M 2017, ' Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer ', Scandinavian Journal of Urology and Nephrology, vol. 51, no. 6, pp. 457-463 . https://doi.org/10.1080/21681805.2017.1354314
Ervandian, M, Høyer, M, Petersen, S E, Sengeloev, L, Hansen, S, Kempel, M M, Meidahl Petersen, P & Borre, M 2017, ' Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer ', Scandinavian Journal of Urology, vol. 51, no. 6, pp. 457-463 . https://doi.org/10.1080/21681805.2017.1354314
Ervandian, M, Høyer, M, Petersen, S, Sengeløv, L, Hansen, S, Kempel, M M, Petersen, P & Borre, M 2017, ' Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer ', Scandinavian Journal of Urology, vol. 51, no. 220, 24, pp. 28-29 . https://doi.org/10.1080/21681805.2017.1332285
Ervandian, M, Hoyer, M, Petersen, S E, Sengelov, L, Hansen, S, Kempel, M M, Petersen, P M & Borre, M 2017, ' Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer ', Scandinavian Journal of Urology and Nephrology, vol. 51, no. 6, pp. 457-463 . https://doi.org/10.1080/21681805.2017.1354314
Ervandian, M, Høyer, M, Petersen, S E, Sengeloev, L, Hansen, S, Kempel, M M, Meidahl Petersen, P & Borre, M 2017, ' Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer ', Scandinavian Journal of Urology, vol. 51, no. 6, pp. 457-463 . https://doi.org/10.1080/21681805.2017.1354314
OBJECTIVE: There is a paucity of knowledge of long-term urinary morbidity in patients treated for prostate cancer (PCa) with radical prostatectomy (RP) and salvage radiotherapy (SRT). Improved long-term survival calls for heightened awareness of late
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::513f1c101d71cce616687f6f9b59c3ee
https://vbn.aau.dk/da/publications/bd625e54-b231-4205-81a0-2a6131acea21
https://vbn.aau.dk/da/publications/bd625e54-b231-4205-81a0-2a6131acea21